Intratumoral Immunotherapy—Update 2019 von Hamid, Omid, Ismail, Rubina, Puzanov, Igor

Volltext

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain von Tawbi, Hussein A, Forsyth, Peter A, Algazi, Alain, Hamid, Omid, Hodi, F. Stephen, Moschos, Stergios J, Khushalani, Nikhil I, Lewis, Karl, Lao, Christopher D, Postow, Michael A, Atkins, Michael B, Ernstoff, Marc S, Reardon, David A, Puzanov, Igor, Kudchadkar, Ragini R, Thomas, Reena P, Tarhini, Ahmad, Pavlick, Anna C, Jiang, Joel, Avila, Alexandre, Demelo, Sheena, Margolin, Kim

Volltext

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma von Schadendorf, Dirk, Hodi, F Stephen, Robert, Caroline, Weber, Jeffrey S, Margolin, Kim, Hamid, Omid, Patt, Debra, Chen, Tai-Tsang, Berman, David M, Wolchok, Jedd D

Volltext

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind st... von Long, Georgina V, Prof, Dummer, Reinhard, Prof, Hamid, Omid, MD, Gajewski, Thomas F, Prof, Caglevic, Christian, MD, Dalle, Stephane, Prof, Arance, Ana, MD, Carlino, Matteo S, PhD, Grob, Jean-Jacques, Prof, Kim, Tae Min, Prof, Demidov, Lev, Prof, Robert, Caroline, Prof, Larkin, James, Prof, Anderson, James R, PhD, Maleski, Janet, BSN, Jones, Mark, MD, Diede, Scott J, MD, Mitchell, Tara C, MD

Volltext

Immunotherapy of cancer in the era of checkpoint inhibitor von Mehmi, Inderjit, Hamid, Omid

Volltext

Pembrolizumab versus Ipilimumab in Advanced Melanoma von Robert, Caroline, Schachter, Jacob, Long, Georgina V, Arance, Ana, Grob, Jean Jacques, Mortier, Laurent, Daud, Adil, Carlino, Matteo S, McNeil, Catriona, Lotem, Michal, Larkin, James, Lorigan, Paul, Neyns, Bart, Blank, Christian U, Hamid, Omid, Mateus, Christine, Shapira-Frommer, Ronnie, Kosh, Michele, Zhou, Honghong, Ibrahim, Nageatte, Ebbinghaus, Scot, Ribas, Antoni

Volltext

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma von Ribas, Antoni, Lawrence, Donald, Atkinson, Victoria, Agarwal, Sachin, Miller, Wilson H., Carlino, Matteo S., Fisher, Rosalie, Long, Georgina V., Hodi, F. Stephen, Tsoi, Jennifer, Grasso, Catherine S., Mookerjee, Bijoyesh, Zhao, Qing, Ghori, Razi, Moreno, Blanca Homet, Ibrahim, Nageatte, Hamid, Omid

Volltext

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study von Robert, Caroline, Prof, Ribas, Antoni, Prof, Schachter, Jacob, Prof, Arance, Ana, MD, Grob, Jean-Jacques, Prof, Mortier, Laurent, Prof, Daud, Adil, Prof, Carlino, Matteo S, MB, McNeil, Catriona M, MD, Lotem, Michal, Prof, Larkin, James M G, Prof, Lorigan, Paul, Prof, Neyns, Bart, Prof, Blank, Christian U, Prof, Petrella, Teresa M, MD, Hamid, Omid, MD, Su, Shu-Chih, PhD, Krepler, Clemens, MD, Ibrahim, Nageatte, MD, Long, Georgina V, Prof

Volltext

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients von Sullivan, Ryan J., Hamid, Omid, Gonzalez, Rene, Infante, Jeffrey R., Patel, Manish R., Hodi, F. Stephen, Lewis, Karl D., Tawbi, Hussein A., Hernandez, Genevive, Wongchenko, Matthew J., Chang, YiMeng, Roberts, Louise, Ballinger, Marcus, Yan, Yibing, Cha, Edward, Hwu, Patrick

Volltext

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma von Hamid, Omid, Schmidt, Henrik, Nissan, Aviram, Ridolfi, Laura, Aamdal, Steinar, Hansson, Johan, Guida, Michele, Hyams, David M, Gómez, Henry, Bastholt, Lars, Chasalow, Scott D, Berman, David

Volltext

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer von Garon, Edward B, Rizvi, Naiyer A, Hui, Rina, Leighl, Natasha, Balmanoukian, Ani S, Eder, Joseph Paul, Patnaik, Amita, Aggarwal, Charu, Gubens, Matthew, Horn, Leora, Carcereny, Enric, Ahn, Myung-Ju, Felip, Enriqueta, Lee, Jong-Seok, Hellmann, Matthew D, Hamid, Omid, Goldman, Jonathan W, Soria, Jean-Charles, Dolled-Filhart, Marisa, Rutledge, Ruth Z, Zhang, Jin, Lunceford, Jared K, Rangwala, Reshma, Lubiniecki, Gregory M, Roach, Charlotte, Emancipator, Kenneth, Gandhi, Leena

Volltext

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial von Kaufman, Howard L, Prof, Russell, Jeffery, MD, Hamid, Omid, MD, Bhatia, Shailender, MD, Terheyden, Patrick, MD, D'Angelo, Sandra P, MD, Shih, Kent C, MD, Lebbé, Céleste, Prof, Linette, Gerald P, MD, Milella, Michele, MD, Brownell, Isaac, MD, Lewis, Karl D, MD, Lorch, Jochen H, MD, Chin, Kevin, MD, Mahnke, Lisa, MD, von Heydebreck, Anja, PhD, Cuillerot, Jean-Marie, MD, Nghiem, Paul, Prof

Volltext

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients von Herbst, Roy S., Soria, Jean-Charles, Kowanetz, Marcin, Fine, Gregg D., Hamid, Omid, Gordon, Michael S., Sosman, Jeffery A., McDermott, David F., Powderly, John D., Gettinger, Scott N., Kohrt, Holbrook E. K., Horn, Leora, Lawrence, Donald P., Rost, Sandra, Leabman, Maya, Xiao, Yuanyuan, Mokatrin, Ahmad, Koeppen, Hartmut, Hegde, Priti S., Mellman, Ira, Chen, Daniel S., Hodi, F. Stephen

Volltext

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study von McDermott, David F, Sosman, Jeffrey A, Sznol, Mario, Massard, Christophe, Gordon, Michael S, Hamid, Omid, Powderly, John D, Infante, Jeffrey R, Fassò, Marcella, Wang, Yan V, Zou, Wei, Hegde, Priti S, Fine, Gregg D, Powles, Thomas

Volltext

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody von Segal, Neil H, Logan, Theodore F, Hodi, F Stephen, McDermott, David, Melero, Ignacio, Hamid, Omid, Schmidt, Henrik, Robert, Caroline, Chiarion-Sileni, Vanna, Ascierto, Paolo A, Maio, Michele, Urba, Walter J, Gangadhar, Tara C, Suryawanshi, Satyendra, Neely, Jaclyn, Jure-Kunkel, Maria, Krishnan, Suba, Kohrt, Holbrook, Sznol, Mario, Levy, Ronald

Volltext

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma von Daud, Adil I, Wolchok, Jedd D, Robert, Caroline, Hwu, Wen-Jen, Weber, Jeffrey S, Ribas, Antoni, Hodi, F Stephen, Joshua, Anthony M, Kefford, Richard, Hersey, Peter, Joseph, Richard, Gangadhar, Tara C, Dronca, Roxana, Patnaik, Amita, Zarour, Hassane, Roach, Charlotte, Toland, Grant, Lunceford, Jared K, Li, Xiaoyun Nicole, Emancipator, Kenneth, Dolled-Filhart, Marisa, Kang, S Peter, Ebbinghaus, Scot, Hamid, Omid

Volltext

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations von Flaherty, Keith T, Infante, Jeffery R, Daud, Adil, Gonzalez, Rene, Kefford, Richard F, Sosman, Jeffrey, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Ibrahim, Nageatte, Kudchadkar, Ragini, Burris, Howard A, Falchook, Gerald, Algazi, Alain, Lewis, Karl, Long, Georgina V, Puzanov, Igor, Lebowitz, Peter, Singh, Ajay, Little, Shonda, Sun, Peng, Allred, Alicia, Ouellet, Daniele, Kim, Kevin B, Patel, Kiran, Weber, Jeffrey

Volltext

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study von Meric-Bernstam, Funda, Sweis, Randy F, Kasper, Stefan, Hamid, Omid, Bhatia, Shailender, Dummer, Reinhard, Stradella, Agostina, Long, Georgina V, Spreafico, Anna, Shimizu, Toshio, Steeghs, Neeltje, Luke, Jason J, McWhirter, Sarah M, Müller, Thomas, Nair, Nitya, Lewis, Nancy, Chen, Xinhui, Bean, Andrew, Kattenhorn, Lisa, Pelletier, Marc, Sandhu, Shahneen

Volltext

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma von Hamid, Omid, Robert, Caroline, Daud, Adil, Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Wolchok, Jedd D, Hersey, Peter, Joseph, Richard W, Weber, Jeffrey S, Dronca, Roxana, Gangadhar, Tara C, Patnaik, Amita, Zarour, Hassane, Joshua, Anthony M, Gergich, Kevin, Elassaiss-Schaap, Jeroen, Algazi, Alain, Mateus, Christine, Boasberg, Peter, Tumeh, Paul C, Chmielowski, Bartosz, Ebbinghaus, Scot W, Li, Xiaoyun Nicole, Kang, S. Peter, Ribas, Antoni

Volltext

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study von Sekulic, Aleksandar, Migden, Michael R, Basset-Seguin, Nicole, Garbe, Claus, Gesierich, Anja, Lao, Christopher D, Miller, Chris, Mortier, Laurent, Murrell, Dedee F, Hamid, Omid, Quevedo, Jorge F, Hou, Jeannie, McKenna, Edward, Dimier, Natalie, Williams, Sarah, Schadendorf, Dirk, Hauschild, Axel

Volltext